MAPT and Parkinson disease: Measurement of other phosphorylated tau species (p-tau181, p-tau217 and p-tau231) in CSF and plasma can discriminate AD patients from cognitively unimpaired subjects and reflect cognitive measures and progression.142 P-tau181 levels have been studied in PD, and their ability to predict disease severity and cognitive decline has been mixed and, therefore, they cannot currently be recommended for trial use.143–145 Other tau species also show promise in AD and need further exploration in PD cohorts.